TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02616484

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dichloroacetate (DCA)
Description: Study medication DCA is a liquid formulation mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12-14 mg/kg/12hr DCA. EGT non-carriers will receive 6-7 mg/kg/12 hr.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive the same volume of placebo in liquid form given during DCA treatment arm. Liquid will be an exact replication of DCA formulation with no DCA added.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive the same volume of placebo in liquid form given during DCA treatment arm. Liquid will be an exact replication of DCA formulation with no DCA added.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Genotype
Description: Participants will be genotyped to determine GSTZ1 haplotype status.

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Genotype
Description: Participants will be genotyped to determine GSTZ1 haplotype status.
Study: NCT05249595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging-based interface to predict human ankle joint motion intent and use in ankle assistive devices
Description: The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by the ultrasound imaging signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging-based interface to predict human ankle joint motion intent and use in ankle assistive devices
Description: The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by the ultrasound imaging signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
Study: NCT05557383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: use peanut ball
Description: The peanut ball was placed between the legs of a woman in the intervention group immediately after she received her epidural and consented to participate in the study.
Study: NCT02284035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir/3TC
Description: MK0518B (Raltegravir/3TC) (300mg/150mg) twice daily, administered orally in the 300/150 mg film-coated tablets according to instructions in the prescribing information.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFV/TDF/FTC
Description: standard combination therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATV/r + TDF/FTC or DRV/r + TDF/FTC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFV plus ABC/3TC or RPV/TDF/FTC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATV/r plus ABC/3TC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAL plus ABC/3TC
Study: NCT01867073

Intervention type: OTHER
Intervention: Biomarker
Study: NCT03941730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study: NCT01084447

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: inspiratory muscle training
Description: This daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)was initially set at 40% of the maximal inspiratory pressure, obtained in the 2nd post-operative day, being adjusted to every new maximal inspiratory pressure measurement.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: In placebo muscular training the daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)no load until the 30th post-operative day.
Study: NCT03941730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study: NCT01554631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose (Glucobay ODT, BAYG5421)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose (Glucobay ODT, BAYG5421)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose (Glucobay, BAYG5421)
Study: NCT02284035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Other ART regimens
Study: NCT02601963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX-103 1.5%
Description: The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX-103 3%
Description: The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle foam (0%)
Description: The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
Study: NCT00966160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir plus Lamivudine/Zidovudine
Description: 400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz plus Lamivudine/Zidovudine
Description: 600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
Study: NCT02176824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Total Sleep deprivation, Sleep Phase Advance, and Bright Light Therapy
Description: Sleep deprivation, Sleep phase advance, and Bright light therapy

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Partial Sleep deprivation, Sleep Phase Delay, and Low amber light.
Study: NCT03526432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, loss of clinical benefit as determined by the investigator.
Study: NCT03941730

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Estradiol
Description: Given PO
Study: NCT02737059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxegol
Description: 25mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naloxegol
Description: 25mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine
Description: 30mg 4 times daily
Study: NCT05249595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface electromypgraphy and ultrasound imaging-based interface to predict human ankle joint motion intent and use in ankle assistive devices
Description: The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by combining sEMG and ultrasound imaging signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface electromypgraphy and ultrasound imaging-based interface to predict human ankle joint motion intent and use in ankle assistive devices
Description: The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by combining sEMG and ultrasound imaging signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
Study: NCT02176824

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Study: NCT02737059

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Codeine
Description: 30mg 4 times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: codeine placebo
Description: 4 times daily (placebo will be made to match the codeine)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: codeine placebo
Description: 4 times daily (placebo will be made to match the codeine)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: naloxegol placebo
Description: placebo will match naloxegol, given daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naloxegol placebo
Description: placebo will match naloxegol, given daily
Study: NCT04786925

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control diet
Description: Control diet: A Mediterranean conventional diet based on the current dietary guidelines of the Spanish Society of Community Nutrition (SENC). Participants were strongly advised to use the Healthy Eating Plate (Harvard) to structure and prepare the main meals (lunch and dinner). In this way, at least ½ of the plate should be composed of vegetables, ¼ of lean protein, and ¼ of low glycemic index carbohydrates. The diet encourages participants to eat 5 times/day (breakfast, lunch, dinner, and two snacks). Overall, the control diet was based on high consumption of vegetables and fruits, whole grains, healthy fats (olive oil), and healthy proteins (legumes, fish, and lean meat). There was not energy restriction in the control diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutriprecision diet
Description: Nutriprecision diet: a Mediterranean balanced diet based on the inclusion of precision foods designed according to the particularities of the senior population. The selected precision foods were a) fruit compote, b) smoothie, c) extruded meat product, d) wholemeal bread, e) wholemeal biscuit and f) microwaveable deep-frozen vegetable products. The diet encourages participants to eat 5 times/day with a conventionally balanced distribution of macronutrients (50% of the total caloric value from carbohydrates, 20% from proteins, and 30% from lipids). There was not energy restriction, although the energy requirements of the participants were adjusted to a BMI of 25 kg/m2 to avoid an overestimate of calorie intake. A mobile application designed and developed to provide volunteers with information about follow-up visits, the assigned diet, recommendations, and messages to motivate them during the intervention. A digital tool for cognitive stimulation.
Study: NCT00810797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: One year after completion of study treatment
Study: NCT02446743

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)
Description: One dose of the vaccine administered intramuscularly in the deltoid area of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)
Description: One dose of the vaccine administered intramuscularly in the deltoid area of the non-dominant arm.
Study: NCT01966692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Formulation 1
Description: Fluticasone Propionate dry powder inhaler Formulation 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Formulation 1
Description: Fluticasone Propionate dry powder inhaler Formulation 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Formulation 1
Description: Fluticasone Propionate dry powder inhaler Formulation 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Formulation 1
Description: Fluticasone Propionate dry powder inhaler Formulation 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Formulation 2
Description: Fluticasone Propionate dry powder inhaler Formulation 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Formulation 2
Description: Fluticasone Propionate dry powder inhaler Formulation 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Formulation 2
Description: Fluticasone Propionate dry powder inhaler Formulation 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Formulation 2
Description: Fluticasone Propionate dry powder inhaler Formulation 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Formulation 3
Description: Fluticasone Propionate dry powder inhaler Formulation 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Formulation 3
Description: Fluticasone Propionate dry powder inhaler Formulation 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Formulation 3
Description: Fluticasone Propionate dry powder inhaler Formulation 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Formulation 3
Description: Fluticasone Propionate dry powder inhaler Formulation 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Formulation 3*
Description: Fluticasone Propionate dry powder inhaler Formulation 3\*~\*(The asterisk) A different set of capsules from the same batch of formulation 3 is given to the subject to assess the within-subject variability and to ensure that the study is sufficiently powered to show bioequivalence between two replicates of the same formulation.
Study: NCT04132180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Mobilization
Description: Range of motion exercises of the upper extremity will be performed under the guidance of the physical therapy team starting on post-operative day 1.
Study: NCT01966692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Formulation 3*
Description: Fluticasone Propionate dry powder inhaler Formulation 3\*~\*(The asterisk) A different set of capsules from the same batch of formulation 3 is given to the subject to assess the within-subject variability and to ensure that the study is sufficiently powered to show bioequivalence between two replicates of the same formulation.
Study: NCT01158118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Study: NCT04132180

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late Mobilization
Description: The patient's grafted upper extremity will be immobilized using an elbow flexion blocking splint until post-operative day 5.
Study: NCT01966692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Formulation 3*
Description: Fluticasone Propionate dry powder inhaler Formulation 3\*~\*(The asterisk) A different set of capsules from the same batch of formulation 3 is given to the subject to assess the within-subject variability and to ensure that the study is sufficiently powered to show bioequivalence between two replicates of the same formulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Formulation 3*
Description: Fluticasone Propionate dry powder inhaler Formulation 3\*~\*(The asterisk) A different set of capsules from the same batch of formulation 3 is given to the subject to assess the within-subject variability and to ensure that the study is sufficiently powered to show bioequivalence between two replicates of the same formulation.
Study: NCT04638504

Intervention type: OTHER
Intervention: ultrasonography
Description: vascular and adipose tissue measurement by ultrasonography
Study: NCT01158118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Study: NCT01166945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-Potassium Clavulanate Combination
Description: All subjects will be started on treatment with 5 days of high dose amoxicillin (90mg/kg) with potassium clavulanate (6.4 mg/kg) twice daily in bottle A. The allocation to group B1 or B2 will be concealed until after the family and subject has signed the assent and consent, respectively. The maximum dose will be 2 gms twice daily. After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin-Potassium Clavulanate Combination
Description: All subjects will be started on treatment with 5 days of high dose amoxicillin (90mg/kg) with potassium clavulanate (6.4 mg/kg) twice daily in bottle A. The allocation to group B1 or B2 will be concealed until after the family and subject has signed the assent and consent, respectively. The maximum dose will be 2 gms twice daily. After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
Study: NCT02825680

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced NCP Support
Description: NCP is a central policy office that provides support to MOVE! program teams through monthly phone calls and technical assistance. Facilities will also have access to the audit and feedback process and barrier buster tool
Study: NCT01166945

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
Study: NCT02825680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced NCP Support
Description: NCP is a central policy office that provides support to MOVE! program teams through monthly phone calls and technical assistance. Facilities will also have access to the audit and feedback process and barrier buster tool

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LEAP
Description: The Learn. Engage. Act. Process (LEAP) intervention relies on virtual (phone and online) coaching based on the IHI Model for Improvement, an online learning platform for clinician teams to share ideas and progress, an audit and feedback process, and a barrier buster tool.
Study: NCT00773149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (CAMPATH 1H) associated to G-CSF
Description: All patients receive Alemtuzumab in 3 successive phases:~Phase A: Test week: 3mg, then 10mg, then 30mg every other day for one week to test for tolerance.~Phase B: 30mg 3 times a week for 12 to 18 administrations until response or progression/failure has been documented.~Phase C: in patients in CR, maintenance with Alemtuzumab: 3 injections one week every 2 months.
Study: NCT03351296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV5FU2
Description: LV5FU2 (Folinic Acid D, L 400 mg/m² day 1, 5FU 400 mg/m² IV bolus, 5FU 2400 mg/m² 48 hours continuous infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV5FU2
Description: LV5FU2 (Folinic Acid D, L 400 mg/m² day 1, 5FU 400 mg/m² IV bolus, 5FU 2400 mg/m² 48 hours continuous infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Streptozocin
Description: streptozotocin 800 mg/m² day 1 every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Streptozocin
Description: streptozotocin 800 mg/m² day 1 every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 750 mg/m² twice daily, days 1-14
Study: NCT03167710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling, manipulation, stretching
Description: HVLA thrust manipulation to elbow, wrist and spine (C5-C6). Dry needling to wrist extensor muscles on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual therapy, exercise, ultrasound
Description: Impairment-based manual therapy, exercise and ultrasound targeting the wrist extensors on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.
Study: NCT02137356

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: standard dose pelvic radiation therapy
Description: radiation therapy to pelvis delivered using standard conformal or IMRT techniques.~50.4-55 Gy